User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

11300

Interactions with Platform & by Email *

INTERACTIONS

1356

Unique # Participated *

PARTICIPANTS

339

Responses Validated *

VALIDATIONS

37

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   A Prelude to Human Reproductive Technologies.....II-1
In-Vitro Fertilization (IVF) – The Leading Infertility Treatment.....II-1
1$100
   Table 1: IVF Practice by Region (2014): Percentage Breakdown of No. of IVF Cycles Performed per year for Global Regions (includes corresponding Graph/Chart).....II-21$350
   Contraceptives.....II-32$200
   Infertility – Overview.....II-5
Table 2: Average Age of First-time Mothers by Year and Country (1970 and 2006) (includes corresponding Graph/Chart).....II-5
Causes.....II-5
1$350
   Table 3: Infertility Causes in the US by Gender: Percentage Share of Female, Male, Female-Male Combined, and Unknown Factors (includes corresponding Graph/Chart).....II-6
Treatment.....II-6
1$350
   Fertility Enhancement Drugs.....II-7
Commonly Used Fertility Drugs.....II-7
Major Brands of Fertility Enhancement/ Ovulation-Induction Drugs.....II-7
1$100
   Gonadotropin Therapy.....II-8
Major Gonadotropin Drugs Used Worldwide.....II-8
1$100
   Assisted Reproductive Technology (ART).....II-9
Table 4: ART Therapy by Gamete Source (2014): Percentage Share Breakdown of Number of Procedures using fresh non-donor eggs, fresh donor eggs, frozen non-donor eggs, frozen donor eggs, and Embryo/Egg Banking (includes corresponding Graph/Chart).....II-9

Table 5: Cumulative Success Rates of IVF by Number of Cycles: Percentage of Success with one, two & three cycles (includes corresponding Graph/Chart).....II-9
1$350
   Table 6: IVF Success Rates by Age Group (2014): No. of IVF Cycles Performed, and Percentage of Successful Pregnancies and Live Births for Women <35, 35-37, 38-40, 41-42, 43-44, and >44 Yrs (includes corresponding Graph/Chart).....II-10
Costs.....II-10
1$350
   Table 7: Average Costs of Different ART Methods.....II-11

Table 8: Average Expenditure Involved for Different Types of Adoption in the US.....II-11
Key Growth Drivers/Trends of the Infertility Market.....II-11
Increasing Maternal Age Leading to Infertility Issues.....II-11
Table 9: Mounting Infertility Rates by Age: Rate of Infertility for Women in 15-29, 30-34, 35-39, and 40-44 Age groups (includes corresponding Graph/Chart).....II-11
1$350
   Higher Rates of Obesity Adversely Impacting Fertility.....II-12
Table 10: Global Obesity Prevalence (2013): Percentage Share Breakdown of Obese Population by Leading Countries (includes corresponding Graph/Chart).....II-12
Cultural Shifts and Society Acceptance of Same-sex Marriage Boost ART.....II-12
1$350
   Table 11: Increase in Same-sex Marriages in the US: Number Estimates of Homosexual Married Couples in 2008, 2010, 2011, 2012 & 2013 (includes corresponding Graph/Chart).....II-13
Medical Tourism on the Rise.....II-13
Market Restraints.....II-13
Variations in Regulations.....II-13
1$350
   Ethical, Religious and Legal Challenges.....II-141$100
   Competitive Landscape.....II-151$100
   CONTRACEPTIVES.....II-16
Table 12: Global Contraceptives Market by Segment (2013): Percentage Share Breakdown of Value Sales by Segment - Oral Contraceptives, Condoms, Implants/Injections, and Others (includes corresponding Graph/Chart).....II-16
1$350
   Major Brands of Oral Birth Control Pills Worldwide by Type and Composition.....II-171$100
   Growth Drivers.....II-18
Market Trends.....II-18
Unmet Contraceptive Needs in Underdeveloped Countries.....II-18
Major Hindrances for Widespread Usage of Condoms.....II-18
1$100
   Increasing Awareness of STDs Creates Additional Demand for Condoms.....II-19
Drospirenone – Controversial Ingredient in Oral Contraceptive Pills.....II-19
1$100
   Contraceptive Manufacturers Focus on Extensive R&D.....II-20
Innovative Condom Promotion Strategies Enhance Product Appeal.....II-20
1$100
   Female Condoms: Empowering the Woman of Today.....II-21
Multifunctional Modern Contraceptives Make a Foray.....II-21
UNFPA Boosts the Contraceptive Market in Emerging Economies.....II-21
1$100
   Emergency Contraception Receives Encouragement from Government.....II-221$100
   Public Health Organizations Spur Condoms Use.....II-23
Favorable Demographic, Social and Economic Trends Strengthens Market
  Prospects.....II-23
1$100
   Table 13: World Population (2012): Population and Percentage Share Breakdown by Age Group - Below 15 Years, 15-64 Years, Above 65 Years (includes corresponding Graph/Chart).....II-24
Competition in the Condoms Market.....II-24
1$350
   Table 14: Leading Players in the Global Condoms Market (2013): Percentage Market Share by Revenue for Ansell, Church & Dwight, Okamoto, Reckitt Benckiser, and Others (includes corresponding Graph/Chart).....II-251$350
   Table 15: Durex' Dominance Worldwide (2013): Market Shares in Select Regions (includes corresponding Graph/Chart).....II-261$350
   Time-lapse Technology Allows Undisturbed Embryo Monitoring.....II-271$100
   Breakthrough Molecular Research to Make Male Contraception a Reality.....II-28
Vasalgel - Revolutionary Male Contraceptive Polymer and Pill.....II-28
1$100
   Prediction of Chromosomal Abnormalities in Cell-1 Stage IVF Embryos.....II-291$100
   ICSI Results not Affected by Spermatozoa Source/Etiology.....II-30
Autologous Mitochondrial Transfer for Enhanced IVF Success.....II-30
1$100
   PGD Assesses Risk of mtDNA Transfer to Child.....II-31
Sunshine Found to Boost IVF Outcomes.....II-31
Newer Innovations in the Contraceptive Market.....II-31
1$100
   Remote-Controlled Female Contraceptives.....II-32
ART Bringing a Paradigm Shift in the Field of Cellular Biology.....II-32
INVOcell Fosters Growth for the ART Industry.....II-32
1$100
   RISUG Technique Gains Recognition.....II-331$100
   Reproduction: Preface.....II-34
Male Reproductive System.....II-34
Female Reproductive System.....II-34
1$100
   Dynamics of Reproductive Endocrinology.....II-351$100
   Human Reproductive Technologies.....II-36
Male/Female Infertility: Causes & Treatment.....II-36
1$100
   Fertility Technologies and Procedures.....II-37
Assisted Reproductive Technology (ART).....II-37
Table 16: Increasing ART Treatments: No. of ART Treatment in 1980, 1990, 2000, and 2010 (includes corresponding Graph/Chart).....II-37
In-Vitro Fertilization (IVF).....II-37
1$350
   Ovarian Stimulation:.....II-38
Egg Retrieval:.....II-38
Fertilization:.....II-38
1$100
   Embryo Transfer:.....II-39
Advantages of IVF.....II-39
Embryo Screening for Inherited Diseases.....II-39
1$100
   Benefits for Single Women/Homosexual Couples.....II-40
Use of Additional Embryos.....II-40
Disadvantages of IVF.....II-40
Multiple Pregnancies.....II-40
Associated Side-Effects.....II-40
Ectopic Pregnancy.....II-40
1$100
   Perinatal Outcomes for Singletons.....II-41
Low Success Rate.....II-41
Intrauterine Insemination (IUI).....II-41
Intracytoplasmic Sperm Injection (ICSI).....II-41
1$100
   Other Fertility Technologies and Advancements.....II-42
Cost-Effectiveness of ART.....II-42
Medical Risks Associated with ART.....II-42
1$100
   Ethical Issues Associated with ART.....II-431$100
   Third-Party Assisted ART.....II-44
Sperm Donation.....II-44
Egg Donation.....II-44
Surrogates or Gestational Carriers.....II-44
CONTRACEPTION – OVERVIEW.....II-44
1$100
   User Involvement.....II-45
Popular Devices and Methods of Contraception.....II-45
Oral Contraceptive Pill.....II-45
2$200
   Intrauterine Devices.....II-471$100
   Barrier Contraceptives.....II-48
Condoms – Types, Benefits, and Risks.....II-48
2$700
   Table 17: Condom Search Volume by Brand (2015): Percentage Share of Online Search Volumes for Leading Brands (includes corresponding Graph/Chart).....II-50
Transdermal Contraceptives.....II-50
Transdermal Patch.....II-50
1$350
   Vaginal Ring.....II-51
Subdermal Implants.....II-51
Comparative Analysis of Contraceptive Implants.....II-51
1$100
   Emergency Contraception.....II-52
Progestin Pills:.....II-52
Ulipristal acetate:.....II-52
Combined Pills:.....II-52
Paragard® Copper-T IUD:.....II-52
1$100
   Comparison of Various Forms of Hormone- based and Non-hormonal Emergency
  Contraception.....II-53
Table 18: Effectiveness of Contraceptive Methods: Percentage of Unwanted Pregnancy Resulting from Various Contraceptive Means (includes corresponding Graph/Chart).....II-53
1$350
   Historical Overview of Human Genetic and Reproductive Technologies.....II-542$200
   Agile Announces USPTO Patent Allowances for New Contraceptive Regimens.....II-56
Genea Biomedx Receives CE Certification for Gavi® and Geri®.....II-56
Agile Announces Patent Issuance for Twirla® Patch.....II-56
Teva Launches Generic Contraceptive Junel® Fe 24.....II-56
Auxogyn’s Eeva™ System Receives FDA Clearance.....II-56
1$100
   Lupin Receives FDA Approval to Market Generic Lutera® (US).....II-57
EPO to Grant Patent to Auxogyn’s Eeva™ Test.....II-57
1$100
   CooperSurgical Acquires Reprogenetics.....II-58
Genea, Merck, and Illumina Form the Global Fertility Alliance.....II-58
Genea Biomedx and Merck Sign Fertility Collaboration Agreement.....II-58
Auxogyn and Fertility Authority Merge to Form Progyny.....II-58
Collaboration Agreement to Expand Access to Pfizer’s Sayana® Press.....II-58
Reprogenetics Enters Into Partnership with Illumina.....II-58
1$100
   Cipla Medpro Enters into Collaboration with Teva Pharmaceuticals.....II-59
Genea Starts European Manufacturing Operations.....II-59
Ferring Pharmaceuticals Partners with Roche.....II-59
OPMEDIC Group Becomes Privately Owned.....II-59
Fertility Group Genea Creates IVF Technology Company Genea Biomedx.....II-59
Auxogyn Enters Into Partnership with Valencia Infertility Institute.....II-59
Agile Enters Into US$15 Million Financing Agreement with Oxford Finance.....II-59
1$100
   Actavis, Inc. (US).....II-60
Ansell Limited (Australia).....II-60
1$100
   Agile Therapeutics, Inc. (US).....II-61
Bayer HealthCare (Germany).....II-61
Church & Dwight Co., Inc. (US).....II-61
1$100
   Cipla Limited (India).....II-62
CellCura ASA (Norway).....II-62
1$100
   Cook Medical (US).....II-63
CooperSurgical (US).....II-63
Ferring Pharmaceuticals (Switzerland).....II-63
1$100
   Fuji Latex Co., Ltd. (Japan).....II-64
Genea Biomedx (Australia).....II-64
Merck KGAA (Germany).....II-64
1$100
   Okamoto Industries (Japan).....II-65
Pfizer Inc. (US).....II-65
Progyny, Inc. (US).....II-65
1$100
   Reckitt Benckiser Group Plc. (UK).....II-66
Sanofi (US).....II-66
1$100
   Teva Pharmaceutical Industries Ltd. (Israel).....II-67
The Female Health Company (US).....II-67
1$100
   Table 19: World Recent Past, Current & Future Analysis for Human Reproductive Technologies by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa, and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....II-681$350
   Table 20: World Historic Review for Human Reproductive Technologies by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa, and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....II-691$350
   Table 21: World 14-Year Perspective for Human Reproductive Technologies by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa, and Latin America Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart).....II-701$350
   Table 22: World Recent Past, Current & Future Analysis for Human Reproductive Technologies by Technology - Contraceptive and Infertility Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....II-711$350
   Table 23: World Historic Review for Human Reproductive Technologies by Technology - Contraceptive and Infertility Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....II-721$350
   Table 24: World 14-Year Perspective for Human Reproductive Technologies by Technology - Percentage Breakdown of Value Sales for Contraceptive and Infertility Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart).....II-731$350
   A. Market Analysis.....III-1
United States: The Leading Market for Human Reproductive Technologies.....III-1
Pill Continues as One of the Most Popular Forms of Contraception.....III-1
1$75
   Table 25: The US Oral Contraceptives Market by Leading Brand (2013): Percentage Market Share Breakdown of Leading Oral Contraceptive Brands in Drugstores (includes corresponding Graph/Chart).....III-2
Condoms Market - Highly Concentrated.....III-2
Table 26: The US Condoms Market by Leading Player (2014): Percentage Market Share Breakdown for Ansell America, Church and Dwight Co., Reckitt Benckiser and Others (includes corresponding Graph/Chart).....III-2
1$200
   Table 27: The US Condoms Market by Leading Player (2014): Percentage Share Breakdown of Drugstore Sales for Ansell America, Church and Dwight Co., Reckitt Benckiser, and Others (includes corresponding Graph/Chart).....III-3
Domestic Condom Players Face Tough Competition from Foreign Brands.....III-3
1$200
   Delayed Childbearing Spells Fortune for the Fertility Industry.....III-4
Table 28: The US Birth Rates by Maternal Age and Year: Rate of Birth in Women in the Age groups <20, 20-29, 30-34, and 35-39+ for the Years 2000, 2006, 2011 & 2013 (includes corresponding Graph/Chart).....III-4
1$200
   Increasing Numbers of Female IVF Users.....III-5
Rise in Successful Births from IVF, Multiple Births Decline Due to Modern
  Methods.....III-5
1$75
   Bill Passed for Same-sex Couples to Avail IVF Treatments.....III-6
Emergency Contraception Pills: Access at Pharmacies, Reimbursement, and State wise
  Policies.....III-6
1$75
   List of State wise Policies on Requiring ERs to Dispense Emergency Contraception and
  Related Services.....III-7
Women’s Awareness and Usage of EC.....III-7
Table 29: Emergency Contraceptive Awareness and Usage Among US Women by Age Group (2015): Percentage of Women who heard of EC & Percentage of Women who used EC (includes corresponding Graph/Chart).....III-7
1$200
   Skyla IUD – Boon for Younger Women.....III-8
Lack of Regulations – Blessing or Drawback?.....III-8
1$75
   Product Launches.....III-91$75
   Strategic Corporate Developments.....III-101$75
   Select Key Players.....III-114$300
   B. Market Analytics.....III-15
Table 30: The US Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-15
1$200
   Table 31: The US Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....III-161$200
   A. Market Analysis.....III-17
Canada Lags Behind in Reproductive Technology.....III-17
Compensation Banned for Surrogacy.....III-17
1$75
   Strategic Corporate Development.....III-18
OPMEDIC Group Inc. – A Key Player.....III-18
1$75
   B. Market Analytics.....III-19
Table 32: Canadian Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-19
1$200
   Table 33: Canadian Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....III-201$200
   A. Market Analysis.....III-21
Oral Contraceptives Not Favored.....III-21
Condoms Usage Continues to Soar.....III-21
1$75
   Major Condom Brands in Japan.....III-22
Crown and Beyond Seven.....III-22
Kimono Condoms.....III-22
Select Key Players.....III-22
1$75
   B. Market Analytics.....III-23
Table 34: Japanese Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-23
1$200
   Table 35: Japanese Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....III-241$200
   A. Market Analysis.....III-25
Table 36: European Market for Contraceptives (2013): Percentage Share Breakdown of Value Sales by Segment - Condoms, Implants/Injections, Oral Contraceptives and Others (includes corresponding Graph/Chart).....III-25
National Testing Labs Join Hands to Find Solutions for Improved Quality of Condom
  Testing.....III-25
2$200
   B. Market Analytics.....III-27
Table 37: European Recent Past, Current & Future Analysis for Human Reproductive Technologies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-27
1$200
   Table 38: European Historic Review for Human Reproductive Technologies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....III-281$200
   Table 39: European 14-Year Perspective for Human Reproductive Technologies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart).....III-291$200
   Market Analysis.....III-30
Table 40: French Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-30
1$200
   Table 41: French Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....III-311$200
   A. Market Analysis.....III-32
Key Players.....III-32
1$75
   B. Market Analytics.....III-33
Table 42: German Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-33
1$200
   Table 43: German Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....III-341$200
   Market Analysis.....III-35
Table 44: Italian Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-35
1$200
   Table 45: Italian Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....III-361$200
   A. Market Analysis.....III-37
Contraceptives – A Mature Market.....III-37
Table 46: Condom Usage in the UK (2013): Breakdown of Usage Rate by Gender and Age (includes corresponding Graph/Chart).....III-37
1$200
   Durex – The Dominant Brand.....III-38
UK Government Approves Mitochondrial Replacement.....III-38
1$75
   Strategic Corporate Development.....III-39
Reckitt Benckiser Group Plc. – A Key Player.....III-39
1$75
   B. Market Analytics.....III-40
Table 47: The UK Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-40
1$200
   Table 48: The UK Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....III-411$200
   Market Analysis.....III-42
Table 49: Spanish Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-42
1$200
   Table 50: Spanish Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....III-431$200
   Market Analysis.....III-44
Table 51: Russian Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-44
1$200
   Table 52: Russian Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....III-451$200
   A. Market Analysis.....III-46
Greece: Fertility Tourism to Mitigate Financial Crisis.....III-46
Strategic Corporate Development.....III-46
Key Players.....III-46
1$75
   B. Market Analytics.....III-47
Table 53: Rest of European Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-47
1$200
   Table 54: Rest of European Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....III-481$200
   A. Market Analysis.....III-49
Government Incentives to Prevent “Low Fertility Trap”.....III-49
Developing Asian Countries Offer Significant Growth Opportunities.....III-49
1$75
   Table 55: China and India Lead Global Population (July 2013): Table Depicting China and India’s Huge Population Vis-a-vis Other Countries’ Population (in Million) by Age Group (includes corresponding Graph/Chart).....III-50
Rising HIV/AIDS Prevalence.....III-50
1$200
   Table 56: Top Twelve Countries in Asia-Pacific with the Highest HIV Incidence (2012) (includes corresponding Graph/Chart).....III-511$200
   Asia-Pacific Contraceptive Market.....III-52
Table 57: Asia-Pacific Market for Contraceptives (2013): Percentage Share Breakdown of Value Sales by Region - China, India and Rest of Asia-Pacific (includes corresponding Graph/Chart).....III-52

Table 58: Asia-Pacific Market for Contraceptives (2013): Percentage Share Breakdown of Value Sales by Segment - Condoms, Implants/Injections, Oral Contraceptives, and Others (includes corresponding Graph/Chart).....III-52
1$200
   B. Market Analytics.....III-53
Table 59: Asia-Pacific Recent Past, Current & Future Analysis for Human Reproductive Technologies by Region - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-53
1$200
   Table 60: Asia-Pacific Historic Review for Human Reproductive Technologies by Region - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....III-541$200
   Table 61: Asia-Pacific 14-Year Perspective for Human Reproductive Technologies by Region - Percentage Breakdown of Value Sales for China, India, and Rest of Asia-Pacific Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart).....III-551$200
   A. Market Analysis.....III-56
An Overview of the Chinese Market for Condoms.....III-56
1$75
   Condoms Market Exhibits Unprecedented Growth.....III-57
Fight against HIV Augurs Well for Condoms Market.....III-57
Chinese Condom Makers Eyeing Smaller Cities to Spruce up Sales.....III-57
1$75
   B. Market Analytics.....III-58
Table 62: Chinese Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-58
1$200
   Table 63: Chinese Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....III-591$200
   A. Market Analysis.....III-60
Preferred Destination for Reproductive Medical Tourism.....III-60
Need for Proper Legislative Framework for Surrogacy and Egg Donation.....III-60
1$75
   Indian Condom Market Overview.....III-61
Social Stigmas Continue to Hamper Growth.....III-61
1$75
   Male Condom Market Witnesses Growth.....III-62
Price Cap on Condoms to Dent Premium Condom Market.....III-62
India Witnesses Decline in Use of Government-Issued Condoms.....III-62
Opportunities Abound for Female Condoms.....III-62
1$75
   NACO’s Initiatives Spurs Female Condoms Use.....III-63
Challenges to Reckon With.....III-63
Usage of Female Condoms Remains a Challenge.....III-63
1$75
   Indian Women Fairly Open to the Concept of Oral Contraceptives.....III-64
Table 64: Indian OTC Contraceptive Pill Market by Brand (2012): Percentage Breakdown of Revenue for Mala-D, Choice, Saheli, Suvidha, Khushi & Others (includes corresponding Graph/Chart).....III-64
1$200
   Cipla Limited – A Key Player.....III-65
B. Market Analytics.....III-65
Table 65: Indian Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-65
1$200
   Table 66: Indian Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....III-661$200
   A. Market Analysis.....III-67
Australia.....III-67
Ban on Commercial Surrogacy.....III-67
Focus on Acquisitions and Consolidation.....III-67
Product Approval.....III-67
1$75
   Strategic Corporate Developments.....III-68
Genea Biomedx (Australia) – A Key Player.....III-68
1$75
   B. Market Analytics.....III-69
Table 67: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-69
1$200
   Table 68: Rest of Asia-Pacific Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....III-701$200
   A. Market Analysis.....III-71
Africa.....III-71
Huge Opportunities in Store for Condom Makers.....III-71
South Africa.....III-71
Family Planning Programs: The Key Source for Condoms.....III-71
1$75
   Strategic Corporate Development.....III-72
Teva Pharmaceutical Industries Ltd. (Israel) – A Key Player.....III-72
1$75
   B. Market Analytics.....III-73
Table 69: The Middle East & Africa Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-73
1$200
   Table 70: The Middle East & Africa Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....III-741$200
   A. Market Analysis.....III-75
Market for Female Condoms Still Nascent.....III-75
Table 71: Latin American Market for Contraceptives (2013): Percentage Share Breakdown of Value Sales by Segment - Condoms, Implants/Injections, Oral Contraceptives and Others (includes corresponding Graph/Chart).....III-75
1$200
   B. Market Analytics.....III-76
Table 72: Latin American Recent Past, Current & Future Analysis for Human Reproductive Technologies by Region - Brazil and Rest of Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-76
1$200
   Table 73: Latin American Historic Review for Human Reproductive Technologies by Region - Brazil and Rest of Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....III-771$200
   Table 74: Latin American 14-Year Perspective for Human Reproductive Technologies by Region - Percentage Breakdown of Value Sales for Brazil and Rest of Latin American Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart).....III-781$200
   A. Market Analysis.....III-79
Role of Condom Social Marketing (CSM).....III-79
National Policy.....III-79
National Regulation.....III-79
1$75
   B. Market Analytics.....III-80
Table 75: Brazilian Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-80
1$200
   Table 76: Brazilian Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....III-811$200
   Market Analysis.....III-82
Table 77: Rest of Latin American Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-82
1$200
   Table 78: Rest of Latin American Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....III-831$200
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com